An interventional study of Video-Based Symptom Management Education in Breast Cancer, sponsored by Antalya Bilim University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Antalya Bilim University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Breast Neoplasms with a site in Turkey — 82 open to participants now, 128 under way, 46 of them phase 3. Breast Neoplasms · Turkey.
Among the 397 studies in Breast Neoplasms with a site in Turkey, this one is the 169th largest by planned enrollment of the 319 interventional ones that give a count, is one of 39 that started in 2026, is one of 182 with no phase, reaches primary completion later than 83 of the 127 other live ones, and was the 397th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →82 of the 397 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Bursa City Hospital · Sites in Turkey
Ages 18–85 · Women only
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ege University · Sites in Turkey
Ages 18+ · Women only
Mucahide Emine Fidancı Kuas · Sites in Turkey
Ages 18–85 · Women only · Healthy volunteers
Ferit Yetik · Sites in Turkey
Ages 18–75 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 98 · Phase 4 5
First in 1996; this study’s year is marked. 39 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 102 across the 319 interventional studies, 84 across the 78 observational. Of the 245 that completed or were terminated, 67 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 397 have an industry lead sponsor. The 10 most frequent:
Antalya Bilim University is the lead sponsor of 16 studies on the registry; 3 are open to participants now.
Antalya Bilim University has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Breast Neoplasms with a site in Turkey that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 31 to your calendar (.ics) → With an account.
Among the 397 studies in Breast Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed as a randomized controlled trial to evaluate the effect of a video-based educational intervention on symptom management self-efficacy and quality of life in women diagnosed with breast cancer who are receiving chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of female patients diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be divided into two groups: an intervention group and a control group.
This study is designed as a randomized controlled trial to evaluate the impact of a video-based educational intervention on self-efficacy for symptom management and quality of life in women diagnosed with breast cancer who are undergoing chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of women diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be assigned to either an intervention group or a control group. The sample size was calculated using the G*Power 3.1.9 software, determining that a minimum of 72 participants-36 in each group-are required. Accounting for potential attrition, the study is planned to include a total of 90 participants, with 45 in the intervention group and 45 in the control group. In addition to routine care, patients in the intervention group will receive support for symptom management through a video-based educational intervention over a period of 8 weeks. Patients in the control group will receive the standard routine care provided at the study site. Data will be collected at three time points: baseline (T0), an interim follow-up (T1), and a final post-test (T2). The primary outcomes of the study are the level of self-efficacy regarding chemotherapy symptom management and quality of life. Secondary outcomes include the usability of the video-based educational intervention and instances of unplanned healthcare utilization (such as emergency department visits or unplanned hospital readmissions). Data collection will involve the use of a "Patient Information Form," the "Chemotherapy Symptom Management Self-Efficacy Scale for Breast Cancer," the "Functional Assessment of Cancer Therapy - Breast (FACT-B)," the "System Usability Scale," and a "Healthcare Utilization and Readmission Form" developed by the researcher. Data obtained from the study will be analyzed using the SPSS software package. It is anticipated that the video-based educational intervention will increase self-efficacy in symptom management among women diagnosed with breast cancer, improve their quality of life, and reduce the utilization of healthcare services, such as emergency department visits and hospital readmissions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to routine care, patients in the intervention group will receive symptom management support over an 8-week period through a video-based educational intervention.
Behavioral: Video-Based Symptom Management Education
Patients in the control group will receive the routine care provided at the center where the study is being conducted.
Participants in the intervention group will receive an 8-week video-based educational intervention in addition to standard care. The web-based platform will provide evidence-based educational videos on chemotherapy-related symptoms and symptom management. Participants will be directed to symptom-specific videos through a rule-based algorithm based on their self-reported symptoms. They will be asked to access the platform at least three times per week and will receive reminder messages twice weekly. Platform usage will be monitored, and post-intervention assessments will be conducted after the 8-week intervention.
Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC)
Symptom management self-efficacy will be assessed using the Symptom Management Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC). Changes in self-efficacy scores will be evaluated across three assessment points.
Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2).
Functional Assessment of Cancer Therapy-Breast (FACT-B)
Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Changes in quality-of-life scores will be evaluated across three assessment points.
Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2).
System Usability Scale (SUS)
System usability will be assessed in the intervention group using the System Usability Scale (SUS) to evaluate participants' perceptions of the video-based educational platform.
Time frame: At the end of the intervention (T2).
Hospital Readmissions
Hospital readmissions will be assessed using a researcher-developed healthcare utilization form, including the occurrence, frequency, and duration of hospital readmissions during the 8-week study period.
Time frame: Week 8 (T2), covering the previous 8 weeks.
Emergency Department Visits
The number and reasons for emergency department visits during the 8-week study period will be assessed using a researcher-developed healthcare utilization form.
Time frame: Week 8 (T2), covering the previous 8 weeks.
Unplanned Healthcare Visits
The frequency and reasons for unplanned outpatient clinic visits and other healthcare facility visits will be assessed using a researcher-developed healthcare utilization form.
Time frame: Week 8 (T2), covering the previous 8 weeks.
Treatment-Related Economic Burden
Treatment-related economic burden will be assessed using a researcher-developed form to evaluate the financial burden associated with healthcare utilization during the study period.
Time frame: Week 8 (T2), covering the previous 8 weeks.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.
Of 2,663 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 2 months is below that.
Counting every sponsor, half of 2,773 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Antalya Bilim University